Pharmaceutical use of vitexin for anti-myocardial ischemia action

An anti-myocardial ischemia, vitexin technology, applied in the field of vitexin, can solve the problem of unclear effective substances of hawthorn leaves

Inactive Publication Date: 2007-03-28
合肥七星医药科技有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although the effect of hawthorn leaf on cardiovascular is positive, as far as the current research is concerned, the pharmacodynamic substances of hawthorn leaf on cardiovascular effect are not clear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use of vitexin for anti-myocardial ischemia action
  • Pharmaceutical use of vitexin for anti-myocardial ischemia action
  • Pharmaceutical use of vitexin for anti-myocardial ischemia action

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1: Effect of vitexin on ECG duration in mice with tracheal clamping

[0034] 1 method:

[0035] 50 Kunming mice, weighing 18-24 g. They were randomly divided into 5 groups: NS control group, vitexin (12, 6, 3 mg·kg -1 ) 3 dosage groups and puerarin (60mg·kg -1 ) Positive medicine control group, 10 rats in each group, ♀♂ half and half. Mice were given tail vein injection (iv) the back of the test drug was fixed on the frog board, a midline neck incision was made, the trachea was separated, and ECG was connected. The trachea was clamped 20 minutes after the administration, and the time was started at the same time. The continuous appearance of a flat line in the ECG II lead (that is, the disappearance of the electrocardiogram) was used as a sign of the death of the mice. The duration (min) of lead II ECG after the mouse trachea was clamped was recorded.

[0036] 2 results

[0037] The results are shown in Table 1. After tracheal clipping, the mice in the NS ...

Embodiment 2

[0041] Example 2: Effect of Vitexin on Myocardial Ischemia Injury in Coronary Artery Ligation Rats

[0042] 1 method:

[0043] 60 rats were randomly divided into 6 groups: sham operation (Sham) group; NS model control group; vitexin (6, 3, 1.5 mg·kg -1 ) 3 dosage groups and puerarin (30mg·kg -1 ) Positive medicine control group, 10 rats in each group, ♀♂ half and half. Rats were treated with 10% chloral hydrate (0.3ml·100g -1 ) intraperitoneal injection (ip) anesthesia, fixed in supine position, median neck incision, separation of the right common carotid artery (CCA), endotracheal intubation, artificial respiration (breathing ratio 1.5:1, 60 times min -1 , tidal volume 70 times min -1 ), open the thoracic cavity at the 3rd to 5th ribs at the left sternal border, expose the heart, and thread a 3 / 8 silk thread through the superficial myocardium at the left border of the conus pulmonary artery and 2 mm from the lower border of the left atrial appendage. The left anterior de...

Embodiment 3

[0055] Example 3: Effect of vitexin on myocardial ischemia injury induced by Iso in rats with myocardial ischemia

[0056] 1 method

[0057] 50 rats (body weight 220-240g) were randomly divided into model group (iv NS+sc Iso), vitexin (6, 3, 1.5 mg·kg -1 ) 3 dose groups (iv vitexin + sc Iso) and puerarin 30mg·kg -1 Group (iv puerarin+scIso), 5 groups in total, 10 rats in each group, half for ♀♂. Among them, Iso (injection dose is 5mg·kg -1 ) was subcutaneously injected into the back of each group 20 minutes after the iv administration of the test drug to induce acute myocardial ischemia and generate ischemic ECG waveforms (lead II, ST segment elevation or depression). Each group recorded an ECG (Lead II) at 30'', 1', 2', 5', 10', and 20' before and after Iso injection. The average value of mv number and ST-segment deviation was used as the index of the degree of myocardial ischemia injury. After 20 minutes, the rats were sacrificed, and the complete myocardial tissue was ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a vitexin with the action for resisting myocardial ischemia, belonging to the field of Chinese medicine technology. Said vitexin is effective component extracted from Chinese medicinal material crataegus leaf.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicines, in particular to vitexin with anti-myocardial ischemia effect. Background technique [0002] Hawthorn leaf (Crataegus pinnatifida) belongs to the Rosaceae plant. It tastes sour and flat in nature. It belongs to the liver meridian. One of the important medicines in blood circulation promoting and stasis medicine. Modern medical research has proved that hawthorn leaves have the functions of strengthening the heart, lowering blood pressure, anti-angina pectoris and lowering blood fat. At present, the most extensive and deepest research on hawthorn leaves is in terms of cardiovascular effects, which can be used clinically to treat coronary heart disease, angina pectoris, hyperlipidemia, arrhythmia, etc. Chemical studies of hawthorn leaves have shown that the main active ingredients in hawthorn leaves are flavonoids. There are nearly 20 kinds of flavonoids in hawthorn leaves, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K36/734A61P9/10
Inventor 邵旭何万龙
Owner 合肥七星医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap